Medical Drugs News
-
Enesi Pharma’s ImplaVax-Enabled, Solid-Dose Recombinant Classical Swine Fever (CSF) Vaccine Produces Immune Responses Superior to Liquid Vaccine
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, is delighted to report positive top-line results from a new study evaluating the immune responses generated by an ImplaVax®-enabled unit solid-dose formulation of classical ...
-
Enesi Pharma Achieves Key Milestone in Development of Thermostable Solid-dose Live Vaccines against Measles and Rubella
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces it has achieved a key milestone in its project to develop needle-free thermostable unit solid-dose live vaccines with retained activity against Measles and Rubella. ...
-
Immunai Recognized by Fast Company’s 2021 World Changing Ideas Awards
Immunai, a New York and Tel Aviv-based biotech company, today announced that it has been recognized as part of Fast Company’s World Changing Ideas Awards. The awards honor the businesses, policies, projects, and concepts that are actively engaged and deeply committed to pursuing innovation when it comes to solving health and climate crises, social injustice, or economic inequality. Immunai ...
By Immunai
-
Enesi Pharma Achieves Preclinical Proof-of-Concept with ImplaVax-Enabled Pandemic Influenza Vaccine
Innovative needle-free injectable unit solid-dose presentation of recombinant H7N9 pandemic flu vaccine, created using Enesi’s ImplaVax technology, generated immune responses comparable with liquid vaccine and demonstrated excellent thermal stability at temperatures up to 40°C for six months. Enesi Pharma (“Enesi”), an innovative biotechnology company developing ...
-
Obsidian Therapeutics To Present Preclinical Data From cytoTIL15 Program at the 24th American Society of Gene and Cell Therapy Annual Meeting
Obsidian Therapeutics, a biotechnology company pioneering engineered cell and gene therapies, today announced that the Company will present at the upcoming 24th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, which will be hosted virtually May 11-14, 2021. The abstract for the poster describes how Obsidian’s cytoTIL15 product (cytoTIL™ therapy engineered with ...
-
Deep Genomics Appoints Jeffrey M. Brown, Ph.D., Vice President of Preclinical Research
Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today the appointment of Jeffrey Brown, Ph.D., Vice President, Preclinical Research. Jeffrey will be responsible for advancing programs into IND-enabling studies, overseeing the discipline of experimental biology, and working with the leadership team on scientific and business strategies. Fueled by their AI ...
-
Bladder Health Foundation Launches Patient Registry for Survivors of Pelvic Radiation Therapy
Pittsburgh, PA – (April 30, 2021) – The Bladder Health Foundation announces the rollout of the first on-line patient registry for pelvic radiation cancer survivors. The online registry is located at www.radiationcystitis.com The Bladder Health Foundation, with support from Lipella Pharmaceuticals Inc., is promoting the awareness of a serious bladder health condition, hemorrhagic ...
-
SEngine Precision Medicine to Present Pan Cancer Data on Predictive Value of PARIS Test at 2021 ASCO Annual Meeting
SEATTLE, April 29, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on live tumor specimens employing its CLIA certified PARIS® Test, today announced that new data from a study summarizing the predictive value of the PARIS® Test across solid tumor cancers will be presented during a poster session (abstract number 2602) at the American ...
-
CanaQuest Files International Mentanine(R) Patent, a Scientific CBD Formulation for Mental Health
Canaquest Medical Corp (OTC PINK:CANQF) (the “Company” or “CanaQuest“), an award-winning Life Science/Pharmaceutical company developing formulations combining cannabinoid molecules with pharmaceutical-grade botanical compounds, today announced the filing of its International Patent, trade named Mentanine, which has demonstrated at least 10-times (10X) the efficacy compared ...
-
Bexson Biomedical Granted USPTO Patent On Proprietary Ketamine Formulation
Bexson Biomedical, Inc., a research-stage company developing therapies and delivery solutions for pain management, addiction and mental health indications, announced today that the U.S. Patent and Trademark Office (USPTO) has granted Bexson U.S. Pat. No. 10,973,780, describing pharmaceutical formulations and treatment methods including the company's BB106 ketamine therapy. Bexson believes the new ...
-
SFA Therapeutics, Inc. announces start of phase 1B clinical trial in the treatment of mild-to-moderate plaque psoriasis
SFA Therapeutics, Inc., a clinical-stage biotechnology company, is pleased to announced the start of our first clinical trial for the treatment of “the appearance of the structure of skin with plaques due to psoriasis.” SFA plans to expand the evaluation of one of its six microbiome-derived drugs, SFA002, in this new trial. This 30-subject open-label clinical trial in patients with ...
-
Exosome Services at Creative Biolabs to Accelerate Lung Cancer Research
As the incidence and mortality of lung cancer rank among the highest all over the world, lung cancer diagnostics and treatment are the most researched paper topics. Research has reported that exosomes derived from lung cancer are the most promising biomarkers for early diagnosis, prognosis, and treatment of lung cancer. With years of experience in this field, Creative Biolabs provides exosome ...
-
Thermo Fisher Scientific Recognizes Significance of FDA Approval of First CAR T Cell Immunotherapy for Multiple Myeloma with Donation to Leukemia and Lymphoma Society
Thermo Fisher Scientific Inc. has made a donation to the Leukemia & Lymphoma Society in recognition of the recent U.S. Food and Drug Administration approval of the first CAR T cell immunotherapy for multiple myeloma developed by Bristol Myers Squibb and bluebird bio. Abecma® (idecabtagene vicleucel; ide-cel) is a chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of ...
-
Zetagen Therapeutics, Inc. Announces European Patent for the Treatment of Stimulating Bone Growth
U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions Latest patent issuance follows previous patents for methods in stimulating bone growth, promote controlled bone creation and repair of large segmental bone defects using ZetaMet™ Company’s intellectual property pipeline targets other oncologic ...
-
Oxford Brain Diagnostics wins funding from the National Institute for Health Research (NIHR) to test Alzheimer’s diagnostic in NHS
Oxford Brain Diagnostics Ltd, a software company focused on developing diagnostics based on changes in the brain at the cellular level, is delighted to announce that we have been awarded funding by the National Institute for Health Research (NIHR) to assess CDM® as a novel and promising tool to identify and predict disease progression amongst patients presenting with mild cognitive impairment ...
-
Seven Bridges Announces Initial Close of Series C Funding from New Strategic Investor to Accelerate Product Development and Commercial Growth
Seven Bridges, the industry-leading bioinformatics ecosystem provider, today announced the close of the first $15 million of a planned $30 million Series C from a new life sciences investor. This investment will support the company in its mission to accelerate scientific discovery and speed the path from raw experimental data to new treatments and diagnostics. “Multi-omics tools are ...
-
Creative Proteomics Provides HPLC-tMS Analysis Service for Metabolomics Profiling
With years of experience in offering professional and high-quality products for academic use and pharmaceutical industries, Creative Proteomics announces HPLC-tMS analysis service for metabolomics profiling. Metabolomics is an omics method to analyze all metabolites of a certain biological component or cell quantitatively and qualitatively under a specific physiological or pathological condition. ...
-
Creative Proteomics Pronalyse Anounces PEGylated Protein Identification Methods for Drug Discovery
Pronalyse is a new division of Creative Proteomics, which is an integrated CRO company with rich experience in providing drug development service for over 10 years. With years of experience in offering professional and high-quality products for academic use and pharmaceutical industries, Creative Proteomics announces diversified PEGylated protein analysis technologies, which can solve important ...
-
GutFlora Omics Platform Releases Total RNA Sequencing Service
GutFlora Omics Platform belongs to Creative Proteomics. With more than 10 years of experience in providing advanced multi-omics services, GutFlora Omics Platform offers services and support to customers through comprehensive intestinal flora research solutions. The product manager has recently announced total RNA sequencing service, which can be applied for the identification of key genes and for ...
-
Berkshire Biomedical Appoints John E. Timberlake as CEO
Berkshire Biomedical, LLC (“Berkshire” or “the Company”), a privately-held digital health company developing a revolutionary virtual care prescription drug delivery and management system only for the Intended User, today announced the appointment of John E. Timberlake as President and Chief Executive Officer. In addition, Mr. Timberlake will serve as a member of the ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you